Eastern Bank Sells 145 Shares of Insulet Corporation $PODD

Eastern Bank decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 21.5% during the 2nd quarter, Holdings Channel.com reports. The fund owned 528 shares of the medical instruments supplier’s stock after selling 145 shares during the quarter. Eastern Bank’s holdings in Insulet were worth $166,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PODD. American Century Companies Inc. lifted its holdings in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Nuveen LLC bought a new position in Insulet during the 1st quarter valued at $74,163,000. Kayne Anderson Rudnick Investment Management LLC lifted its stake in Insulet by 1,316.5% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after acquiring an additional 179,850 shares in the last quarter. Vanguard Group Inc. lifted its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock valued at $2,276,553,000 after acquiring an additional 178,976 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in Insulet by 23.4% during the 1st quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier’s stock valued at $166,198,000 after acquiring an additional 120,197 shares in the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on PODD shares. Citigroup reissued a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. The Goldman Sachs Group dropped their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Oppenheimer lifted their price target on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $347.67.

Insulet Stock Performance

Shares of PODD opened at $314.52 on Monday. The firm has a market cap of $22.14 billion, a PE ratio of 95.60, a PEG ratio of 2.61 and a beta of 1.40. The stock’s fifty day moving average price is $323.75 and its two-hundred day moving average price is $300.64. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a 1 year low of $226.50 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. During the same period in the previous year, the business posted $0.55 EPS. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.